噻托溴铵吸入粉雾剂联合羧甲司坦片对COPD患者临床症状及肺功能的影响

Effects of Tiotropium Bromide Inhalation Powder Mist Combined with Carbocisteine Tablets on Clinical Symptoms and Lung Function in COPD Patients

目的探讨噻托溴铵吸入粉雾剂联合羧甲司坦片在慢性阻塞性肺疾病中的应用价值,分析该联合用药方案对主要症状与患者肺功能指标的影响。方法方便选取2022年2月—2024年2月黔东南州苗族侗族自治州人民医院收治的86例慢性阻塞性肺疾病患者为研究对象,遵循随机分组原则将其划分为两组,每组43例。对照组采用噻托溴铵治疗,观察组在对照组基础上采用羧甲司坦片,比较两组急性加重次数、症状评分、肺功能指标、相关炎症指标、总有效率、不良反应。结果观察组总有效率为97.67%(42/43),高于对照组的83.72%(36/43),差异有统计学意义(χ^(2)=4.962,P<0.05)。观察组急性加重次数、症状评分以及各项炎症因子指标水平均低于对照组,肺活量、第1秒用力呼气容积高于对照组,差异有统计学意义(P均<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论在慢性阻塞性肺疾病患者中,噻托溴铵与羧甲司坦合用有助于改善其临床症状与肺功能指标,减少急性加重次数,下调相关炎症指标表达水平,且安全性良好。

Objective To explore the application value of tiotropium bromide inhalation powder mist combined with carbocisteine tablets in chronic obstructive pulmonary disease,and to analyze the effects of this combination of medication regimen on the main symptoms and pulmonary function indexes of patients.Methods A total of 86 patients with chronic obstructive pulmonary disease admitted to the Qiandongnan Miao and Dong Autonomous Prefecture People's Hospital from February 2022 to February 2024 were conveniently selected as the study objects and were divided into two groups according to the principle of random grouping,with 43 cases in each group.The control group was treated with tiotropium bromide,and the observation group was treated with carboxymesteine tablets on the basis of the control group.The number of acute exacerbations,score of symptom,pulmonary function indexes,related inflammatory indexes,total effective rate and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.67%(42/43),which was higher than that of the control group 83.72%(36/43),the difference was statistically significant(χ^(2)=4.962,P<0.05).The levels of acute exacerbation times,symptom score and inflammatory factors in the observation group were lower than those in the control group,and the lung capacity and forced expiratory volume in the first second were higher than those in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In patients with chronic obstructive pulmonary disease,the combination of tiotropium bromide and carboxymesteine can improve clinical symptoms and lung function indicators,reduce the number of acute exacerbations,and reduce the expression level of related inflammatory indicators,with good safety.